Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its ...

Texas Attorney General Ken Paxton on Thursday announced a lawsuit alleging that Eli Lilly (NYSE:LLY) bribed his state's medical providers in a bid to persuade them to prescribe the company’s weight ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.